HDL nanoparticles targeting sonic hedgehog subtype medulloblastoma

Area of Science:

• Oncology
• Nanotechnology
• Biochemistry

Background:

• Medulloblastoma is a common pediatric brain cancer with unmet therapeutic needs.
• The sonic hedgehog (SHH) subtype, comprising 25% of cases, relies on cholesterol signaling for growth.
• Targeting cholesterol pathways presents a potential therapeutic strategy.

Purpose of the Study:

• To investigate the efficacy of biomimetic high-density lipoprotein nanoparticles (HDL NPs) in targeting SHH medulloblastoma.
• To assess the impact of HDL NPs on cholesterol signaling, cancer cell proliferation, and cancer stem cells (CSCs).

Main Methods:

• Utilized HDL NPs designed to bind scavenger receptor type B-1 (SCARB1), blocking cholesterol uptake.
• Demonstrated HDL NP uptake in SCARB1-expressing medulloblastoma cells.
• Assessed the effects of HDL NPs on cell proliferation, colony formation, and CSC populations in medulloblastoma and Ewing sarcoma models.

Main Results:

• HDL NPs were effectively taken up by medulloblastoma cells.
• Cholesterol levels were depleted in cancer cells treated with HDL NPs.
• HDL NPs significantly inhibited proliferation, disrupted colony formation, and depleted CSCs in medulloblastoma and Ewing sarcoma.

Conclusions:

• HDL NPs show promise as a targeted therapy for SHH medulloblastoma by disrupting essential cholesterol signaling.
• This approach offers a novel strategy for treating medulloblastoma and potentially other hedgehog-driven cancers.